Strong lenses, fertility growth, new legal drag
- CooperVision is the profit engine, with Q2 fiscal 2026 sales up 8% to $723.5 million.
- CooperSurgical sales also rose 8% to $358.0 million, helped by 13% growth in Fertility.
- The big problem is a $271.6 million litigation charge tied to an embryo culture media recall.
- If that charge is truly one time, reported profit understates the earning power of the core business.
- Investors still need proof that the legal bill is capped and Japan returns to growth.
Good quarter, ugly legal headline
Cooper's latest quarter was hard to read at first glance. The reported numbers were hit by a $271.6 million litigation charge in CooperSurgical tied to an embryo culture media recall. That pushed CooperSurgical to a $225.0 million operating loss for the quarter and turned the total company into a reported operating loss.
The operating picture under that charge looked much better. CooperVision sales grew 8% to $723.5 million, and its operating margin was 30%. CooperSurgical sales also grew 8% to $358.0 million, led by 13% growth in Fertility.
The bull case is that Cooper still has two good end markets: vision care and fertility care. Contact lenses are repeat purchases, and fertility services are tied to long-term demand from families and clinics. If the recall cost does not grow much from here, the stock may be pricing in a worse business than Cooper actually has.
The bear case is that the legal issue may not be finished. The company has noted over 1,500 claimants and a $324.1 million accrual before insurance. If the final cost is higher, cash flow and buyback or deal plans could be squeezed. Japan softness in CooperVision is another open issue.
Repeat lenses and clinic tools
Cooper makes money by selling medical products to eye doctors, fertility clinics, hospitals, and women's health providers. CooperVision sells contact lenses used daily, every two weeks, or monthly. That gives the company a repeat order base instead of a one-time sale.
CooperSurgical sells more than 600 products and services in fertility and women's health. Its Fertility line supports in-vitro fertilization, which is a process where eggs are fertilized outside the body. Products include lab media, devices, egg and sperm donation services, and genetic testing.
The moat comes from product know-how, doctor relationships, and a wide product list. In contact lenses, advanced materials like silicone hydrogel matter because comfort and eye health affect repeat use. In fertility, clinics need reliable products and services across many steps of a sensitive process.
Where this can break is clear. A product recall can create lawsuits and hurt trust. A supply issue can limit lens production. A poor ERP rollout, which means a major internal software change, can slow orders, billing, or financial reporting.
What Cooper sells
Biofinity contact lenses
Biofinity is CooperVision's highest-grossing brand. It helps anchor the repeat-purchase contact lens business.
Toric and multifocal lenses
These lenses treat astigmatism and presbyopia, which are more complex vision needs. In Q2 fiscal 2026, this category grew 11%.
MyDay and clariti 1 day
These daily lenses serve customers who want fresh lenses each day. Daily lenses can support steady repeat demand.
MiSight 1 day
MiSight is used for myopia management in children. It was the first FDA-approved lens to slow myopia progression in children.
Fertility products and services
This line supports IVF clinics with devices, media, donor services, and genetic testing. Fertility sales grew 13% in Q2 fiscal 2026.
Paragard and women's health devices
CooperSurgical also sells contraception and office or surgical products for women's health providers. This gives the segment a broader base than fertility alone.
Two segments, one bigger engine
Segment mix is based on Q2 fiscal 2026 net sales: CooperVision had $723.5 million and CooperSurgical had $358.0 million. CooperVision is the larger profit driver, while CooperSurgical is now carrying the legal overhang.
What could break the thesis
Embryo media litigation grows
High impact · Medium oddsCooperSurgical recorded a $271.6 million litigation expense tied to an embryo culture media recall. The company has noted over 1,500 claimants and a $324.1 million accrual before insurance. The risk is that the final settlement or court cost is higher than the amount already set aside.
Japan stays weak in vision care
Medium impact · Medium oddsCooperVision is the main earnings engine, so regional weakness matters. The internal thesis flags continued softness in Japan, a key market. If Japan does not stabilize, CooperVision growth could slow even if other regions hold up.
Fertility growth proves temporary
Medium impact · Medium oddsFertility sales grew 13% in Q2 fiscal 2026, which is central to the bull case. That growth was helped by consumable products and genetic testing. If clinics pull back or demand normalizes, CooperSurgical may not offset legal and operating costs as well as hoped.
ERP rollout disrupts operations
Medium impact · Medium oddsCooper is in a multiyear process of putting new ERP systems into CooperVision and CooperSurgical. ERP is core business software used for orders, inventory, finance, and reporting. A bad rollout could create shipping delays, reporting errors, or extra costs.
Supply or regulatory shock
Medium impact · Low oddsCooper depends on specialized materials and regulated products. A shortage of key contact lens materials, or a new FDA or foreign regulator issue, could slow product launches or production. This matters because the company sells medical devices, not simple consumer goods.
In one breath
What does The Cooper Companies do?
Cooper is a medical device company with two main businesses. CooperVision sells contact lenses, and CooperSurgical sells fertility and women's health products and services.
Why did Cooper report such weak profit in Q2 fiscal 2026?
The quarter was hit by a $271.6 million litigation charge in CooperSurgical. Without that charge, the core sales trends were strong, with both main segments growing 8%.
What is the main thing investors should watch now?
The key watch item is the final cost of the embryo culture media litigation. Investors should also watch whether Fertility can keep growing at a double-digit rate and whether Japan improves for CooperVision.